Effectiveness and safety study of tezepelumab in adults & adolescent participants with severe asthma in the United States - PASSAGE

Inclusion Criteria

• • Male or female participant must be 12 years of age or older, at the time of signing the informed consent form or assent.
• • Documented physician-diagnosed asthma for at least 12 months prior to enrollment and confirmed by the Investigator not to be due to alternative diagnoses.
• • Documented treatment with medium- to high dose ICS as per Global Initiative for Asthma (GINA) guidelines (GINA 2021) for at least 12 months prior to enrollment.
• • Use of additional asthma maintenance controller medication(s) in addition to ICS for at least 12 months prior to enrollment. The additional maintenance controller medication may be contained in a combination product (eg, ICS/ long-acting β-agonist (LABA)).
• • Documented history of at least 2 asthma exacerbations during the 12 months prior to enrollment.
• • Physician decision that participant is eligible for treatment with tezepelumab according to the approved United States product insert (USPI).
• • Currently receiving care from specialist physicians (eg, pulmonologists and/or allergists).
• • Provision of signed and dated written informed consent form.